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Summary ER content of primary tumour tissue has been examined in 704 patients presenting with operable
breast cancer. The median follow-up is now 84 months and no patient has received adjuvant therapy of any
kind.
ER status is related to histological grade, menopausal status, initial site of metastases and subsequent
response to endocrine therapy.
A significant advantage in terms of survival is found in ER positive patients which is confined to those
lymph node positive at mastectomy. DFI is also significantly related to ER status in lymph node positive
patients.
Survival after the symptomatic presentation of metastases and the institution of endocrine therapy is
prolonged in patents with ER positive tumours. The overall response rate to endocrine therapy in assessable
patients with ER positive tumours is 32%. By combining the ER status and histological grade of tumour
tissue, a group of patients comprising 28% of those assessable to endocrine therapy can be identified (ER
positive, grade I and 11) with a response rate of 46%.
The early studies of tumour oestrogen receptor (ER) content,
in patients with primary breast cancer, found a prolonged
disease free interval (DFI) and a favourable prognosis in
patients presenting with ER positive tumours (Knight et al.,
1977; Allegra et al., 1979; Cooke et al., 1979; Osborne et al.,
1980; Samaan et al., 1981; Neifield et al., 1982 and Paterson
et al., 1982). These reports were based on relatively few
women with limited follow up and have been criticised as
they often included patients receiving post operative chemo-
therapy. In addition the ER status was not analysed in
primary tumour tissue in all cases.
In 1978 we presented our initial results from a series of
300 patients followed for a maximum of 48 months after
mastectomy (Maynard et al., 1978a). At that time a
significantly improved DFI was found in women with ER
positive tumours. No patient had received adjuvant
chemotherapy and the ER status was recorded in primary
tumour tissue in all cases. The improvement in DFI in ER
positive patients was particularly marked when only those
with involved lymph nodes at mastectomy were examined.
A later report on this series established a relationship
between ER content of tumour tissue and histological grade
(Maynard et al., 1978h). An early study of the survival of
these patients confirmed a highly significant early advantage
for post menopausal women presenting with ER positive
tumours (Bishop et al., 1979). After further follow-up the
DFI advantage for all patients with ER positive tumours
was lost, but remained when those with positive lymph
nodes were examined separately. Overall ER positivity of
primary tumour continued to confer a significant survival
advantage (Blamey et al., 1980).
More recent reports with, in some cases, a longer follow-
up have suggested that any initial advantage in terms of
disease free interval is not maintained after a further
observation period (Hilf et al., 1980; Kinne et al., 1981;
Caldarola et al., 1983; Alanko et al., 1984; Aamdal et al.,
1984; Par] et al., 1984; Howat et al., 1985; Raemaekers et al.,
1985). Several of these studies have however included
patients receiving adjuvant therapy.
The absence of tumour ER in patients with advanced
disease is an acknowledged predictor of poor response to
endocrine therapy (McGuire et al., 1975; Roberts ct al.,
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1978; Allegra et al., 1980; Cant et al., 1985). It was noted by
our group that remission rates improve with increasing
concentrations of ER (Campbell et al., 1981a). We also
found an association between the site of initial metastases
and ER content of tumour tissue; ER positive tumours
preferentially metastasise to bone (Campbell et al., 1981b).
We now report our long term findings from a large series
of patients with a minimum follow up of 35 months and a
maximum follow up of 145 months (median=84 months).
None of the patients considered for analysis received
adjuvant therapy of any kind and in all cases the ER status
was recorded in the primary tumour.
Patients and methods
The oestrogen receptor content of primary tumour tissue was
measured from 753 patients receiving treatment for operable
breast cancer between January 1974 and March 1983. These
constitute all women in whom the tumour ER status is
known, from 1,000 consecutively treated patients under the
care of one surgeon (RWB).
A series of other factors were simultaneously recorded at
mastectomy as part of an ongoing project (Nottingham/
Tenovus Institute) to study potential prognostic factors for
,early' breast cancer (Haybittle et al., 1982).
No patients in the Nottingham series received adjuvant
hormone therapy although a small number received
cytotoxic agents immediately after operation (n=49). These
patients have been excluded leaving 704 patients for further
analysis.
All patients presented under 70 years of age and received
either simple/subcutaneous mastectomy (n=570) or lumpec-
tomy and irradiation (n= 134) as primary treatment. In the
latter group the field of irradiation was confined to the
breast and did not include regional nodes. The menopausal
status was recorded at presentation and confirmed using
LH and FSH levels in women who had undergone previous
hysterectomy or were within 5 years of natural cessation of
menstruation.
Disease was staged at mastectomy using a triple node
biopsy technique (Blamey ct atl., 1980). In brief one node was
sampled from around the axillary vein (apical), one from the
low axilla and one from the internal mammary chain.
Patients were staged A: with no nodal involvement, B: with68 M.R. WILLIAMS et al.
low axillary involvement and C: if either apical or internal
mammary nodes were proved to contain tumour on
histological examination.
Tumour size was measured from the fresh mastectomy
specimen and a sample of the tumour was 'flash' frozen in
liquid nitrogen prior to storage at -190 C until assay.
Assays for ER were performed using the Dextran coated
charcoal method and tumours with an ER content in excess
of 5 fmol mg-' cytosolic protein were classified as ER
positive (Nicholson et al., 1981).
Histological grade was assessed in all tumours under the
supervision of one pathologist (CWE) using a modification
of Bloom and Richardson's criteria (Elston et al., 1980).
Patients were followed in a post mastectomy clinic at three
monthly intervals for 18 months, six monthly intervals for
three years and annually thereafter.
The disease free interval was recorded as the time to
presentation of local or regional recurrence requiring
treatment (DXT or excision of axillary nodes) or, in their
absence, to the development of distant metastases.
The relationship between ER status and the sites of first
presentation of metastases was examined in 290 patients
developing distant metastases after grouping into three
categories: A: bone metastases, B: lung metastases and
C: visceral metastases (liver, brain, intra abdominal). In all
these patients systemic therapy had not been prescribed for
recurrent local or regional disease before the symptomatic
presentation of distant metastases.
Survival after the initiation of therapy was examined in all
patients (n =204) receiving endocrine therapy as initial
treatment for distant metastases after dividing patients
according to the ER status and histological grade of primary
tumour tissue. Again all patients receiving prior systemic
therapy were excluded.
Two hundred and thirty-five patients with assessable
disease received endocrine therapy as initial treatment for
local or systemic recurrence. One hundred and eighty-eight
of these received endocrine treatment for distant metastases
and the remainder for progression of locoregional disease
despite radiotherapy.
Endocrine therapy consisted of oophorectomy in pre-
menopausal and Tamoxifen in post-menopausal patients.
Criteria for response were strict and followed UICC and BBG
guidelines, requiring a minimum remission of six months
duration (British Breast Group, 1974; Hayward et cal., 1977).
External review of response was obtained (Dr A. Howell,
Christie Hospital, Manchester).
Analysis of the survival times and DFIs of the patients
was performed by life table analysis and the significance of
differences between selected groups was assessed using log
rank analysis (Peto et al., 1977).
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Results
The overall incidence of ER positivity in this series was 57%.
1. Associations hetnt'een ER staitus ancd histological gradle,
vnimph niode stalge, m11enopaIusal status candtl tumiour siz:e
No correlation was found between ER status and lymph
node stage or tumour size. A highly significant relationship
existed between ER status and histological grade, ER
activity occurred more frequently in well differentiated
tumours (Table I). There was also a significant relationship
between ER and menopausal status, ER positive tumours
occurring more frequently in patients presenting after the
menopause. Fifty-one percent of premenopausal patients
presented with ER positive tumours compared with 59% of
those post-menopausal at presentation (Z2 =4.77; P<0.05).
Table I ER status versus histological grade
Gr-ade
ER positive 87 168 146
ER negative 31 92 180
/ = 39.5; P<0.001.
2. ER status, DFI and sureilal
When all patients were considered no overall association was
found between ER status and DFI (Z'2=0.97; 1 df; P>0.1).
However in patients with positive lymph nodes at
mastectomy a significantly prolonged DFI occurred in those
with ER positive tumours (Figure 1). When only patients
developing a recurrence within 36 months from mastectomy
were examined a significantly prolonged DFI again occurred
in those with ER positive tumours (not illustrated, P<0.05).
A weak correlation between patients with ER positive
tumours and prolonged survival was maintained throughout
the entire study period (Figure 2). This became more marked
when patients with positive nodes were examined separately
and was maintained after further subdivision according to
histological grade (Figure 3). ER positivity conferred no
significant survival advantage in lymph node negative patients
(Figure 4). The overall survival advantage for all ER posi-
tive patients was lost after subdivision according to histo-
logical grade (ER positive versus ER negative: grade I & 1I:
2 =0.68; 1 df; P>0.5; grade III: x2 =0.29; 1 df; P>0.05).
ER neg. lymph node neg.
ER pos. lymph node neg.
Ch. Sq. 0.47 1 df
p>0.1
ER pos. lymph node pos.
ER neg. lymph node pos.
Chi. Sq. 16.7 1 df
p<0.001
Time (months)
A 185 176 162 156 148 137 118 103 86 75 63 62 52 50 42 38
B 216 211 200190 174 158 140 122 110 96 74 69 52 48 35 33
C 185 170 148128 112 104 95 84 68 58 44 40 29 25 14 12
D 118 103 79 58 45 39 30 24 19 14 9 8 6 6 3 3
Figure 1 Disease free interval ER positive versus ER negative tumours after division according to lymph node status.uu
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Figure 2 Overall survival ER positive versus ER negative tumours.
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Figure 3 Overall survival in lymph node positive patients after division according to histological grade and ER status.
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Figure 4 Overall survival ER positive versus ER negative tumours after division according to lymph node status.
100
80
> 60
U) 40
20
1 (r) ----&-70 M.R. WILLIAMS et al.
3. ER staitus cand value, response to endocrine therapy, and site
of initial distant metastasis.
A strong correlation was found between response to
endocrine therapy and ER status. The overall response rate
in this series was 23%. Thirty-two percent of patients with
ER positive tumours subsequently responded while only
10% of those with ER negative tumours remained in
remission 6 months after commencing treatment (Table II).
Response rates in ER positive patients improved with
increasing ER concentrations, ranging between 19% and
610% in patients with a tumour ER concentration below 40
and above 200 fmol mg- cytosolic protein respectively
(Figure 5).
Table III ER and histological grade versus initial site of metastases
Site of metastases
Tottal
Bone Lung Visceral patients
ER positive 118 (72%) 64 (39,9) 38 (230))) 165
ER negative 57 (46%o) 39 (31,) 56 (45)),) 125
Grades I & II 88 (72o%) 37 (30'/%) 25 (20Wo) 122
Grade III 87 (52%) 66 (39(0) 94 (56°o) 168
Percentage of 'total patients' with involvement at each site shown
in brackets. Numbers at each site do not summate to 'total patients'
due to metastatic involvement in more than one site in many
patients.
Table 11 ER and histological grade versus endocrine response
Response No response Response rate
ER positive 44 94 320))
ER negative 10 87 1000
Grades I & II 37 56 400'
Grade III 17 125 12%
ER ver-sus response Z2= 15; P<0.001.Grade versus response y2 24.6;
P<0.001.
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of all other patients responded and in the 29% of assessable
patients with grade III, ER negative tumours, less than 5%
remained in remission after 6 months therapy.
4. ER status and survival after endocrine therapj Jbr distant
metastasis
A clear relationship existed between patients with ER
positive primary tumours and prolonged survival after the
onset of distant metastasis. Of 122 patients with ER positive
tumours receiving first line endocrine therapy 50% were
alive at 18 months compared with 18% of 82 patients with
ER negative tumours receiving similar treatment (Figure 6).
When survival after symptomatic presentation of metas-
tases was examined in patients showing objective signs of
response, those with ER positive tumours had a clear
survival advantage over the few patients with ER negative
tumours. This did not occur in patients failing to respond to
endocrine therapy where there was little survival advantage
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Figure 5 Response as a function of ER concentration.
The site of first documented distant recurrence also
correlated well with ER status. One hundred and sixty-five
patients with ER positive tumours developed distant
metastases before receiving systemic therapy of any kind.
One hundred and eighteen (72%) of these had bone involve-
ment at diagnosis while 38 (23%) had visceral involvement.
Of 125 patients developing metastases from ER negative
tumours, 56 (45%) had visceral involvement and 57 (46%)
presented with bone metastases (Table III).
Histological grade of primary tumour tissue was also
significantly related to site of initial metastasis and
subsequent response to endocrine therapy (Tables 11 & III).
By combining ER status and histological grade, a group of
patients (grade I and II, ER positive: 28% of total) were
identified with a response rate of 46%. In contrast only 14%
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Figure 7 Survival after metastases: ER positive versus ER negative tumours in patients showing response or no response to
endocrine therapy.
for patients with ER positive tumours (Figure 7). Interestingly
when patients were grouped according to histological grade
and ER status, the major survival advantage after metastases
was confined to patients with well differentiated ER positive
tumours (grade I and II). Patients with poorly differentiated
(grade III) ER positive tumours had similar survival charac-
teristics to all those with ER negative tumours (Figure 8).
Discussion
This study confirms the importance of ER status when used
alone as a prognostic indicator in patients presenting with
lymph node positive primary breast cancer. The incidence of
ER positivity is similar to that reported by Alanko (63%)
and Raemackers (66%) but is lower than that found in other
series: Par] (76%); Aamdal (72%) and Howell (70%). Our
exclusion criteria for patients presenting over 70 years of age
may in part account for these differences.
The long term discrimination in overall survival achieved
by oestrogen receptor status is lost when all patients are
grouped according to histological grade. This agrees with
our previous finding that the prognostic importance of ER is
largely dependent upon its association with grade. ER status
does not appear as an independently significant prognostic
factor when included with grade in a multivariate analysis
(Haybittle et al., 1982). If histological grade is not assessed
then the use of ER combined with node stage provides a
good prognostic discriminant. The prognostic importance of
ER is not however entirely dependent upon its association
with grade as in lymph node positive patients, even after
further subdivision according to histological grade, survival
is significantly prolonged in patients with ER positive
tumours. After longer follow-up, with more events, this
advantage for patients with ER positive tumours may also
appear in patients lymph node negative at mastectomy.
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Our findings are at variance with those reported by
Alanko et al. (1984) and Raemaekers et al. (1985) who
found no association between DFI (or survival) and ER
status even after stratification according to lymph node stage
at mastectomy. The mean follow-up of patients in these
series was 41 and 76 months respectively. They suggest that
previous reports, showing an advantage for patients with ER
positive tumours, may have been influenced by the addition
of adjuvant therapy at mastectomy. In contrast Howat et al.
(1985) reported a significant improvement in relapse free
survival for patients with positive axillary nodes when ER
was present in primary tumour. However this advantage for
ER positive patients was confined to those with relatively
few nodes (1 to 3) involved at mastectomy.
The major advantage for patients with ER positive
tumours occurs after the onset of recurrent disease, as DFI is
unaffected by ER status overall. This suggests a survival
advantage conferred on this group by either the effect of
treatment response or the site of initial metastasis. Both
these factors are seen to correlate with ER status. These
findings are in agreement with those reported by Howell et
al. (1984) and Howat et al. (1985) where, despite no overall
difference in disease free interval, improved survival after
first relapse of disease was noted in patients with ER
positive tumours.
In our series in those patients presenting with poorly
differentiated (grade III) carcinoma there is little advantage
in terms of survival after the appearance of metastases for
those with ER positive tumours. This again underlines the
importance of histological grade, even in advanced disease.
The improved survival after metastases seen only in patients
with well differentiated (grade I and II) ER positive tumours
may suggest that this group has an advantage in terms of
tumour growth rate (as reflected by tumour grade) allowing
endocrine therapies to have their maximal effect. In addition
the association between tumours of poor histological
differentiation and visceral metastases may be an important
factor.
The low response rate of 23% reflects our strict
assessment criteria. ER negativity is confirmed as a predictor
of poor response to subsequent endocrine manipulation.
However it is to be noted that 10% of patients still
responded to endocrine treatment despite the absence of ER
in primary tumour tissue. A strong association is also found
between histological grade and therapeutic response, in
agreement with reports from another centre (Millis et al.,
1981; Masters et al., 1986). This in part may indicate that
patients with low grade tumours, which have a naturally
slow growth rate, have time to maintain a remission for the
required six months defined by the response criteria adopted.
It is to be noted that tumour grading has been performed
under the supervision of one experienced pathologist (CWE)
with a particular interest in this field. In this situation
histological differentiation has similar potential to ER status
in predicting subsequent response to endocrine therapy using
BBG criteria. The combination of ER status and histological
grade is able to achieve the greatest discrimination between
those patients most likely to benefit from hormone
manipulation and those in whom disease prQgresses.
It is of great interest that, even in the presence of objective
signs of response, patients with ER negative tumours have
poor survival after symptoms from metastases first occur.
This may represent a misclassification of response in these
patients as, indeed, their long term survival on therapy was
similar to all those progressing despite treatment. This
increases the confidence with which ER status predicts a
failure of endocrine treatment in terms of survivial after
metastases.
Therapeutic implications in the management of patients
with advanced breast cancer can be drawn from these
findings. By combining the results of ER assays with
hisotological grade a group of patients comprising 28% of
the total is identified (ER positive, grade I and II). These
patients enjoy relatively good survival after commencing first
line endocrine therapy which exceeds 40% at three years. In
this situation therefore endocrine therapy should be
instituted in all cases. However patients with ER positive
grade III tumours and those with ER negative tumours have
equally poor survival characteristics after metastases are
confirmed. In these situations the addition of alternative
treatments may be indicated at an early stage. We suggest
that where possible an accurate assessment of histological
grade should be performed at the same time as oestrogen
receptor analyses to identify those patients who behave
favourably after the initiation of endocrine treatment.
In conclusion a strong correlation is found between ER
status in primary breast carcinoma and histological grade.
ER status relates weakly to overall survival but not to the
disease free interval. ER status relates strongly to both DFI
and overall survival when lymph node positive patients are
examined separately. These findings in lymph node positive
patients are maintained even after further subdivision
according to histological grade. ER status relates to the site
of initial metastases and both ER status and quantitative
levels relate to subsequent response to endocrine therapy.
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